Poly(adenosine diphosphate–ribose) polymerase-1 (PARP1) inhibitors have improved ovarian cancer treatment outcomes. However, clinical response remains heterogeneous. Existing biomarkers, mainly breast cancer susceptibility genes 1 and 2 (BRCA1/2), are suboptimal. New tools are needed to guide patient selection. In this study, [¹⁸F]fluorthanatrace ([¹⁸F]FTT), a PET radiotracer for imaging PARP1, was compared with [¹⁸F]FDG and tumor features commonly assessed in ovarian cancer. Methods: Subjects with epithelial ovarian cancer underwent both [¹⁸F]FTT and [¹⁸F]FDG PET before new oncologic treatment. The SUV_max of [¹⁸F]FTT and [¹⁸F]FDG was compared between lesions. [¹⁸F]FTT SUV_max was compared with tumor location, tumor grade, and germline or somatic BRCA1/2 status. Linear mixed models were fitted to identify subject-level differences. Results: Fifty-five lesions were identified in 14 subjects. No correlation was found between [¹⁸F]FTT SUV_max and [¹⁸F]FDG SUV_max per lesion, supporting distinct molecular targets. [¹⁸F]FTT uptake varied widely across lesions, with no significant differences between mean SUV_max and tumor location, grade, or BRCA1/2 status. Conclusion: Our findings suggest that [¹⁸F]FTT PET may provide unique information on ovarian cancer distinct from [¹⁸F]FDG PET and commonly assessed tumor features. Our results imply a wide range of PARP1 expression in the studied ovarian tumors not explained by [¹⁸F]FDG PET, location, grade, or mutational status.

聚（二磷酸腺苷-核糖）聚合酶 1 （PARP1） 抑制剂改善了卵巢癌的治疗结果。然而，临床反应仍然存在异质性。现有的生物标志物，主要是乳腺癌易感基因 1 和 2 （BRCA1/2），是次优的。需要新的工具来指导患者选择。在这项研究中，[¹⁸F]fluorthanatrace （[¹⁸F]FTT） 是一种用于 PARP1 成像的 PET 放射性示踪剂，与 [¹⁸F]FDG 和卵巢癌中通常评估的肿瘤特征进行了比较。方法：上皮性卵巢癌患者在新的肿瘤治疗前接受了 [¹⁸F]FTT 和 [¹⁸F]FDG PET。比较病灶之间 [¹⁸F]FTT 和 [¹⁸F]FDG 的 SUV_最大值。[¹⁸个地址]将 FTT SUV_max 与肿瘤位置、肿瘤分级和种系或体细胞 BRCA1/2 状态进行比较。拟合线性混合模型以识别受试者水平的差异。结果：在 14 例受试者中确定了 55 个病灶。每个病灶的 [¹⁸F]FTT SUV_max 和 [¹⁸F]FDG SUV_max 之间没有发现相关性，支持不同的分子靶标。[¹⁸个地址]FTT 摄取在不同病灶之间差异很大，平均 SUV_max 与肿瘤位置、分级或 BRCA1/2 状态之间没有显著差异。结论：我们的研究结果表明，[¹⁸F]FTT PET 可能提供不同于 [¹⁸F]FDG PET 和通常评估的肿瘤特征的卵巢癌独特信息。我们的结果表明，在研究的卵巢肿瘤中，PARP1 表达范围很广，无法用 [¹⁸F]FDG PET、位置、分级或突变状态来解释。